U.S. flag

An official website of the United States government

NM_000492.4(CFTR):c.1687T>C (p.Tyr563His) AND Cystic fibrosis

Germline classification:
Pathogenic (2 submissions)
Last evaluated:
Aug 12, 2024
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000757828.3

Allele description [Variation Report for NM_000492.4(CFTR):c.1687T>C (p.Tyr563His)]

NM_000492.4(CFTR):c.1687T>C (p.Tyr563His)

Gene:
CFTR:CF transmembrane conductance regulator [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
7q31.2
Genomic location:
Preferred name:
NM_000492.4(CFTR):c.1687T>C (p.Tyr563His)
HGVS:
  • NC_000007.14:g.117590360T>C
  • NG_016465.4:g.129577T>C
  • NM_000492.4:c.1687T>CMANE SELECT
  • NP_000483.3:p.Tyr563His
  • LRG_663:g.129577T>C
  • NC_000007.13:g.117230414T>C
Protein change:
Y563H
Links:
dbSNP: rs121909006
NCBI 1000 Genomes Browser:
rs121909006
Molecular consequence:
  • NM_000492.4:c.1687T>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Cystic fibrosis (CF)
Synonyms:
Mucoviscidosis
Identifiers:
MONDO: MONDO:0009061; MedGen: C0010674; Orphanet: 586; OMIM: 219700

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000886314Mendelics
criteria provided, single submitter

(Mendelics Assertion Criteria 2017)
Pathogenic
(Nov 5, 2018)
unknownclinical testing

Citation Link,

SCV005380630Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Pathogenic
(Aug 12, 2024)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedunknownyesnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Distribution of CFTR mutations in the Czech population: positive impact of integrated clinical and laboratory expertise, detection of novel/de novo alleles and relevance for related/derived populations.

Křenková P, Piskáčková T, Holubová A, Balaščaková M, Krulišová V, Čamajová J, Turnovec M, Libik M, Norambuena P, Štambergová A, Dvořáková L, Skalická V, Bartošová J, Kučerová T, Fila L, Zemková D, Vávrová V, Koudová M, Macek M, Krebsová A, Macek M Jr.

J Cyst Fibros. 2013 Sep;12(5):532-7. doi: 10.1016/j.jcf.2012.12.002. Epub 2012 Dec 29.

PubMed [citation]
PMID:
23276700

Extensive CFTR sequencing through NGS in Brazilian individuals with cystic fibrosis: unravelling regional discrepancies in the country.

da Silva Filho LVRF, Maróstica PJC, Athanazio RA, Reis FJC, Damaceno N, Paes AT, Hira AY, Schlesinger D, Kok F, Amaral MD; Brazilian Cystic Fibrosis Patient Registry Contributors Team..

J Cyst Fibros. 2021 May;20(3):473-484. doi: 10.1016/j.jcf.2020.08.007. Epub 2020 Aug 18.

PubMed [citation]
PMID:
32819855
See all PubMed Citations (3)

Details of each submission

From Mendelics, SCV000886314.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownyesnot providednot providednot providednot providednot providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV005380630.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

Variant summary: CFTR c.1687T>C (p.Tyr563His) results in a conservative amino acid change located in the ABC transporter-like, ATP-binding domain (IPR003439) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 250432 control chromosomes. c.1687T>C has been reported in the literature in individuals affected with Cystic Fibrosis without reported second variant (e.g. Krenkova_2013, daSilvaFilho_2021). These reports do not provide unequivocal conclusions about association of the variant with Cystic Fibrosis. A different variant affecting the same codon has been classified as pathogenic by our lab (c.1687T>A, p.Tyr563Asn), supporting the critical relevance of codon 563 to CFTR protein function. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect resulted in approximately 2% of normal chloride channel conductance relative to wild type (e.g., Bihler_2024). The following publications have been ascertained in the context of this evaluation (PMID: 38388235, 23276700, 32819855). ClinVar contains an entry for this variant (Variation ID: 618927). Based on the evidence outlined above, the variant was classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 26, 2024